key: cord-1050199-eckww6hb authors: Schneider, M. M.; Emmenegger, M.; Xu, C. K.; Condado Morales, I.; Turelli, P.; Zimmermann, M. R.; Frey, B. M.; Fiedler, S.; Denninger, V.; Meisl, G.; Kosmoliaptsis, V.; Fiegler, H.; Trono, D.; Knowles, T. P. J.; Aguzzi, A. A. title: Microfluidic Affinity Profiling reveals a Broad Range of Target Affinities for Anti-SARS-CoV-2 Antibodies in Plasma of Covid Survivors date: 2020-09-23 journal: nan DOI: 10.1101/2020.09.20.20196907 sha: 3d8fbbac3dc5bdbf2038e7cc005174b26dd6e304 doc_id: 1050199 cord_uid: eckww6hb The clinical outcome of SARS-CoV-2 infections can range from asymptomatic to lethal, and is thought to be crucially shaped by the quality of the immune response which includes antibody titres and affinity for their targets. Using Microfluidic Antibody Affinity Profiling (MAAP), we determined the aggregate affinities and concentrations of anti-SARS-CoV-2 antibodies in plasma samples of 42 seropositive individuals, 23 of whom were confirmed to be SARS-CoV-2-positive by PCR testing. We found that dissociation constants (Kd) of anti-RBD antibodies spanned more than two orders of magnitude from 80 pM to 25 nM, despite having similar antibody concentrations. Individual patients showed progressively higher antibody concentrations but constant Kd values, suggesting that affinities did not mature over time. 33 sera showed affinities higher than that of the CoV2 spike for its ACE2 receptor. Accordingly, addition of seropositive plasma to pre-formed spike-ACE2 receptor complexes led to their dissociation. Finally, we observed that the RBD of HKU1, OC43, and SARS-CoV coronaviruses, but not unrelated control proteins, were able to compete substantially with the RBD of SARS-CoV-2 in solution. Therefore, the affinity of total plasma immunoglobulins to SARS-CoV-2 is an indicator of the quality of the immune response to SARS-CoV-2, and may help select the most efficacious samples for therapeutic plasmapheresis. The emerging severe-acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has not only led to an enormous increase in mortality all over the world 2 , but is also having a severe impact on and impairment of health-care systems, economic, and socio-economic indicators. Therefore, the rapid development of drugs and vaccines is of utmost importance to tackle the crisis. An understanding of the biochemical processes involved in the SARS-CoV-2 infection, particularly relating to the immune response, will be required to best design both treatments and vaccines. Adaptive humoral immune responses are crucial for defending hosts against incoming viruses 3 . However, the individual immune responses to any given virus are highly variable, and this can translate into different efficacies of viral clearance. Several studies have investigated antibodies generated during SARS-CoV-2 infection, thereby dissecting the antibody occurrence upon immune response [4] [5] [6] [7] [8] , antibody cross-reactivity 9 , disease prevalence in certain geographical areas 1, 10, 11 , and the temporal evolution of the antibody response on the population level 1, 10, 11 . Furthermore, multiple ongoing studies focus on the applicability of antibodies for therapeutic purposes 12 , including plasmapheresis [13] [14] [15] [16] [17] , which may be a promising therapeutic strategy 17 . In such studies, occurrence of IgG antibodies has consistently been detected within two weeks after infection 1, 4, 6 . The biophysical parameters that govern the interaction between any antibody and its cognate antigen are its binding affinity and its concentration. Antibody titres are usually determined by enzyme-linked immunosorbent assay (ELISA) of serially-diluted samples, and represent a convolution of antibody affinity and concentration. Samples which contain low concentrations of high-affinity antibodies, and those with large amounts of low-affinity would exhibit identical immunological titres. These two scenarios may result in distinct biological properties which cannot be predicted by simple titration. While there have been efforts to infer antibody affinities through such approaches 18, 19 , these methods are often fraught with large error margins. Here we determined affinity and concentration directly in plasma samples of seropositive individuals using Microfluidic Antibody Affinity Profiling (MAAP) 20 . We quantified both parameters in 39 seropositive individuals who presented either mild symptoms or were asymptomatic, demonstrating a comparable immune response which is independent of the symptoms displayed. By longitudinally monitoring antibody responses in severely symptomatic COVID-19 patients, we found an increase in antibody concentration, but no change in affinity, over the course of infection. In all samples with detectable binding, the binding affinity was stronger than the interaction between SARS-CoV-2 spike protein (S) and its associate receptor, the angiotensin converting enzyme 2 (ACE2), by which the virus infects host cells 21 . Our results are consistent with the idea that the immune response to SARS-CoV-. CC-BY-NC 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.20.20196907 doi: medRxiv preprint 2 is predominately driven by inhibitory antibodies that effectively reduce the binding affinity of the target to the receptor. Determination of Antibody Affinity and Concentration in Plasma. As part of a large-scale seroprevalence survey, plasma from over 10,000 healthy donors from the blood donation service (BDS) of the canton of Zurich was investigated for the presence of antibodies against SARS-CoV-2 Spike (S), receptor binding domain (RBD) and nucleocapsid proteins 1 . Seropositivity was defined as having a probability of being seropositive of ≥0.5, using our tripartite immunoassay 1 . To characterise the affinity-concentration relationship, we selected 19 healthy donors with sufficient residual plasma volume with a probability ≥0.85 to be seropositive, who were not diagnosed with SARS-CoV-2 previously. In addition, we investigated 20 PCR-confirmed convalescent individuals and three hospitalised patients with acute COVID-19 pneumonia, of which both cohorts were positive on ELISA as well (Fig. 1) . The demographic characteristics of the seropositive collective are summarised in Table S1. Figure 1 : Principle of the study. First, we selected seropositive individuals based on a large-scale sero-survey 1 and performed four assays: Microfluidic Antibody Affinity Profiling (MAAP), cell-based plaque neutralisation assay, ACE2 competition assay and RBD cross-reactivity. For MAAP, blood is drawn from individuals who underwent an infection with SARS-CoV-2 as confirmed by ELISA, independent of symptoms they display. The blood cells are removed by centrifugation and fluorescently labelled RBD protein is added to the plasma, leading to complex formation between the antibodies abundant in the plasma and the extrinsically added fluorescently conjugated protein. The ACE2 competition assay and RBD cross-reactivity assay, which rely on co-incubation of the RBD with antibodies and a competitor molecule, show a decrease in hydrodynamic radius upon successful competition. . CC-BY-NC 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.20.20196907 doi: medRxiv preprint As an immune target, we selected the RBD of the spike protein, since it is crucial for antibodydependent neutralisation by preventing host cell entry, and thus may be most significant in the immune response to SARS-CoV-2 22 . We determined the affinities and concentrations of RBD-reactive antibodies by measuring the equilibrium binding of antibodies in the plasma of seropositive individuals with the RBD directly in solution through MAAP, whereby the effective hydrodynamic radius of the Alexa647labelled RBD protein was monitored. The measured radius increase upon complex formation with RBD-reactive antibodies allows detection and quantification of antibody binding (Fig. 2) . Such measurements can be performed directly in plasma/serum, so that samples are not perturbed by additional purification procedures. These binding measurements report on the combined response of all antibodies targeting different RBD epitopes at different affinities. In case there were multiple antibodies with different affinity present in the plasma sample, we are selective towards tighter binders (Fig. S6 ). First, we characterised the serum antibodies from 20 convalescent individuals and 17 healthy blood donors. 2 individuals could not be analysed on our platform due to presence of an excessively high serum background fluorescence, a known, yet rare, limitation of our assay 20 . A size increase, indicating significant binding to the RBD domain, was detected and quantified in all samples (Fig. 2a) , with the exception of 6 healthy donor samples which we did not observe binding to the RBD domain by MAAP (Fig. S2) . Considering all samples investigated, we found that the antibody concentration for the polyclonal antibody mixture falls into a relatively narrow range of 8-69 nM assuming a binding stoichiometry of 1:2 antibody:RBD, with two exceptions that display relatively high concentrations (192 nM and 298 nM). In contrast, the Kd values were more variable, ranging from subnanomolar (in which case no lower bound on Kd can be determined) to 25 nM (Fig. 2b) . From physical considerations in order for significant binding to occur, the antibody binding site concentration must exceed the Kd. Accordingly, our data demonstrate that in all cases where quantifiable binding was detected, [Ab] > 2*Kd (Fig. 2b) . Interestingly, also the 3 hospitalised patients displayed affinities and concentrations in a similar range, although their antibody concentration higher than the majority of samples (Fig. 2b) . This suggest that the antibody response to a SARS-CoV-2 infection is fairly similar, independent of the symptoms displayed by an individual. We next determined the dissociation constant for the interaction between spike protein and ACE2 receptor to be 30 nM (Fig. S3) . This is higher than the Kd for almost all the plasma samples of the seropositive individuals. This indicates that, during the immune response, antibodies with higher affinity than the virus-receptor interaction are produced. Moreover, the relatively little excess in the concentration of antibody binding sites compared to Kd in most . CC-BY-NC 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.20.20196907 doi: medRxiv preprint individuals may imply that affinity maturation is not continued beyond these minimum requirement, and only sufficient antibody is produced that to compete with the ACE2 to RBD interaction. Moreover, our binding equilibria are thus achieved under physiologically relevant conditions and our in-solution measurements allow to determine both the antibody affinity and concentration. As discussed previously 20 , the commonly used EC50 values obtained through surface measurements may depend on both the antibody affinity and concentration. In contrast, MAAP allows simultaneous deconvolution of these two fundamental physicochemical properties which describe antibody binding, a clear advantage over common surface-based techniques. To understand how affinity and concentration of the antibodies evolve over early timepoints, we investigated antibody maturation in three hospitalised COVID-19 patients. All three patients suffered from diabetes, with patients 2 and 3 presenting additional cardiovascular conditions, and requiring hospitalisation due to pneumonia. Analyses were performed for patient 1 (days post onset (DPO) 9 -13), patient 2 (DPO 8 -14), and patient 3 (DPO 7 -15). In all cases, no binding was detected until day 12 by MAAP, consistent with the ELISA data 1 and previous is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.20.20196907 doi: medRxiv preprint literature 4,6 . Analysis of plasma samples taken from patients 1 and 2, taken one-two days apart, respectively, indicate that antibody concentration increases with no change in binding affinity (DPO 12 and 13 for patient 1, and DPO 12 and 14 for patient 2) (Fig. 2c) . For patient three, only one time point could be effectively measured (Fig. 2c) . These data, therefore, further support the hypothesis that, after producing an antibody with sufficiently high affinity, the affinity is not increased further, in favour of increasing antibody production. While our data are limited to just two timepoints in two patients, this effect is striking, and in contrast to previous work on Ebola, where antibody affinity has been found to increase as a function of time 23 . Neutralisation and ACE2-Receptor Binding Competition. From an immunological point of view, the interaction between the RBD region of the spike protein and the ACE2 receptor needs to be inhibited, mostly via antibodies that bind to the RBD. First, we investigated the degree of neutralisation on wildtype virus using a conventional virus neutralisation assay. From 37 seropositive individuals tested, 17 neutralisation activity when diluted 1:20 but no longer at 1:80, 10 had titres between 1:80 and 1:320 and 4 displayed titres < 1:320, while 6 did not show any neutralisation. (Fig. 3a-b and Fig. S4 ). The 6 samples which did not show neutralisation had relatively low titres against RBD on ELISA, and four of them did not show significant binding on the MAAP assay (Table S2) . We then aimed to compare these results to the inhibitory effect of antibodies directed against the RBD of the spike protein using our microfluidics-based methodology. We therein incubated the samples of seropositive individuals, S1 and fluorescently-labelled ACE2 protein simultaneously (Fig. 3c) . The observed hydrodynamic radius, R h, of the ACE2 protein increases in the presence of S1 and seronegative plasma samples, as expected from binding of ACE2 to the S1 protein (Fig. 3d) . However, upon the addition of seropositive plasma samples, this size increase is abrogated, indicating that the antibodies preventing binding of the S1 to ACE2 as such are inhibitory. This was observed for every sample for which we could determine a dissociation constant apart from one exception where we could determine a dissociation constant but did not observe neutralisation in the cell-based assay. The subsequent comparison of cell-based neutralisation with affinity and concentration show that the lowest concentration of antibody for which neutralisation is observed ranges between 80 pM to 2 nM, a relatively narrow range. Therefore, we hypothesise that two of the prerequisites for neutralisation are (a) an antibody concentration in the range between 80 pM to 2 nM and (b) an affinity of the RBD that is stronger for the antibody than for the ACE2 receptor (Fig. 3 e-f ). This novel, microfluidic neutralisation surrogate is in good agreement with the cell-based neutralisation assays ( Fig. 3g and Table S2 ). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.20.20196907 doi: medRxiv preprint Cross-Reactivity to other RBDs. Often discussed is a potential cross-reactivity of SARS-CoV-2 antibodies to RBD from related coronaviruses. We further investigated this cross- Figure 3 : (a) Cell-based plaque neutralisation assay. Example plate. We observe neutralisastion at dilution 1:20 for blood samples from individuals 6, 7, and 8, 1:80 for individuals 1, 2, 3 and 5, and 1:320 for individual 4. All images shown in Fig. S4. (b) Cell-based plaque neutralisation assay. From 37 seropositive individuals tested, 6 showed no neutralisation, 19 showed a titer < 1:20, with 11 having titres between 1:80 and 1:320 and 4 having titres < 1:320. (c) Scheme of the competition assay. We incubate the spike protein with the ACE2 receptor, leading to a complex formation. Upon addition of plasma, this complex is disassembled. (d) Hydrodynamic radius of ACE2 in presence of spike protein in plasma of seropositive individual. When seropositive samples are used, no binding is detected, demonstrating the capability of the antibodies present in plasma to inhibit the interaction relevant for cellular uptake of the virus; in contrast, pre-pandemic plasma (PPP) samples do not inhibit the spike-ACE2 interaction. (e) Plot of the critical concentration at which neutralisation is observed vs. dissociation constant. We calculated this from the titers in the cell-plaque neutralisation assay and the concentrations determined in Fig. 2b . In order to be neutralising, the antibody needs to have an affinity tighter than the interaction to ACE2 (dashed horizontal line/orange region) and needs to lie in the concentration range 80 pM to 2 nM. Below this concentration, the amount of antibody does not enable neutralisation. Error bars omitted for visibility. The individual for whom no neutralisation is observable has an insufficiently high antibody concentration. The cut-off values were derived from the ROC curve Fig. 3g , with the optimal ratio between true positive and false positive. (f) Comparison between the hydrodynamic radius surrogate for neutralisation and the cell-based neutralisation data, with the same non-detectability regions and yielding a similar picture as Fig. 3e . As cut-off value, we used 5.5 nm, as shown in Fig. 3d and Fig. 3g . The red line represents the size of the bound complex. Error bars omitted for visibility. (g) ROC curve comparing the outcome of the microfluidic experiment with the cell-plaque based experiments. At a cut-off value of 5.5 nm (Fig. 3d) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.20.20196907 doi: medRxiv preprint reactivity of the antibodies for ten, randomly chosen, individuals from the previously tested cohort, 5 of which were healthy donors (I10, I11, I16, I18 and I36), and five of which were convalescent individuals (I22,I23,I25,I26,I28) ( Fig. 4 and S5) . For this purpose, we incubated both labelled SARS-CoV-2 RBD and unlabelled RBD for other coronaviruses (SARS-CoV, HKU1 and OC43) with the plasma samples. If these RBDs are able to compete for binding, we would observe a decrease in hydrodynamic radius relative to the SARS-CoV-2 RBD measurement. For 5 individuals, most cross reactivity was observed for the SARS-CoV RBD, samples from two individuals showed most cross-reactivity was observed for RBD from OC43 and three samples for RBD from HKU1. Our data highlights that a potent immune response against one coronavirus can elicit cross-reactive antibodies against RBD domains of other coronaviruses. This finding may be crucial at identifying different SARS-CoV-2 strains that may be circulating in the future, as it becomes assumable that immunity from a pre-infection with one SARS-CoV-2 strain is protective against a different strand as well. Antibody responses against a pathogen involve three critical features: The specific epitope that is targeted, antibody concentration, and the affinity of its interaction with the antigen. Here, we characterised the latter two for the RBD domain of the spike protein, using Microfluidic Antibody Affinity Profiling, directly in solution. We have observed that the net antibody concentration is fairly uniform across different individuals with varying symptom severity (8-69 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.20.20196907 doi: medRxiv preprint nM), while a higher variability in Kd is observed, ranging from sub-nanomolar to tens of nanomolar. However, in all cases where binding in plasma was significant enough to be quantified (i.e. where [Ab] > 2Kd), this interaction was strong enough to prevent the interaction between the ACE2 receptor and the spike protein. This finding was confirmed with a virusbased plaque neutralisation assay, where all samples, but one, which were able to outcompete ACE2 binding in vitro showed neutralisation in vivo as well. Lastly, we identified that the immune response against SARS-CoV-2 holds the potential to recognise RBD epitopes from other coronaviruses, suggesting that antibodies capable of neutralisation may be produced by activated memory B cells even when triggered by an alternative future SARS- The relationship between antibody concentration and affinity is likely to have consequences for plasmapheresis, together with targeting the appropriate epitopes for efficient neutralisation. During plasmapheresis treatment, the donor plasma is diluted by roughly a factor of ten upon transfusion into the patient 17 . For the donor antibodies to still bind viral proteins effectively following this dilution, in the case where the patient has produced no antibodies, the antibody binding site concentration should thus exceed the Kd by at least a factor of ten. We hypothesise that the success of plasmapheresis is dependent on the ratio of [Ab]/Kd of the neutralising fraction of antibodies. Therefore, only the patients with very strong Kd values should be considered as blood donors for plasmapheresis, a parameter that cannot be sufficiently accessed with conventional methods. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2020. . https://doi.org /10.1101 /10. /2020 Reagents. SARS-CoV-2 RBD, ACE2-receptor protein and SARS-CoV-2 spike S1 protein were purchased from SinoBio (Eschborn, DE). RBDs from SARS-CoV, HKU1, and OC43 were purified as outlined 1 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2020. in linear space for ρf (using µ and σ determined through measurements of the purified RBD). The likelihood function was considered to be Gaussian, with a standard deviation obtained through replicate measurements. ACE2 Competition. S1 protein (10 nM) and ACE2 receptor protein (10 nM is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.20.20196907 doi: medRxiv preprint Early plateau of SARS-CoV-2 seroprevalence identified by tripartite immunoassay in a large population. medRxiv World Health Organisation. Coronavirus Disease (COVID-19) Weekly Eidemiological Update 1 Innate immunity: an overview Antibody responses to SARS-CoV-2 in patients with COVID-19 Antibody Detection and Dynamic Characteristics in Patients with COVID-19 Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Detection of antibodies against SARS-CoV-2 in patients with COVID-19 SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv, 2020 Is COVID-19 receiving ADE from other coronaviruses? Microb The Promise and Peril of Antibody Testing for COVID-19 COVID-19 Antibody Seroprevalence Neutralizing antibodies mediate virus-immune pathology of COVID-19 Convalescent plasma as a potential therapy for COVID-19 Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike The convalescent sera option for containing COVID-19 Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19 Monoclonal antibody binding affinity determined by microchip-based capillary electrophoresis Scatchard Plot and Heterogeneity in Binding Affinity of Labeled and Unlabeled Ligand Microfluidic Antibody Affinity Profiling for In-Solution Characterisation of Alloantibody -HLA Interactions in Human Serum. bioRxiv Endothelial cell infection and endotheliitis in COVID-19 Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design Kinetic fingerprints differentiate anti-Aβ therapies. bioRxiv All authors wish to thank their entire teams for support in the lab. We thank Tom Scheidt (IMB, Mainz) who provided graphics for TPJK is a member of the board of directors of Fluidic Analytics. AA is a member of the board of directors of Mabylon AG which has funded antibody-related work in the Aguzzi lab in the past. VD, SF, HF are employees of Fluidic Analytics. All other authors declare no competing interests.